Clinical Trial Update: Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A phase II trial evaluating carboplatin and paclitaxel with or without atezolizumab before surgery in newly diagnosed stage II–III triple-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Tecentriq (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-18